https://www.selleckchem.com/pr....oducts/ro-61-8048.ht
88 (10.6) vs. 45.08 (10.6); MCS, 49.45 (11.1) vs. 48.1 (11.9); CES-D, 10.11 (9.8) vs. 10.86 (10.5); POMS-SF, 23.95 (38.6) vs. 26.35 (38.8); MOS-SSS, 79.2 (21.2) vs. 78.66 (21.2)) or over time. One exception was slightly worse mean scores at month 9 in MCS (Cohen's d, - 0.22; 95% CI, - 0.38, - 0.06) and POMS (Cohen's d, 0.23; 95% CI, 0.07, 0.39) for EE-S vs. S-DE. CONCLUSIONS The implementation strategies were equivalent. IMPLICATIONS FOR CANCER SURVIVORS Enhancing support may be considered before delivering not-in-person intervention
Like
Comment
Share
